• Dextrose (D-glucose): Applied Workflows for Tumor & Metaboli

  2026-05-14

  Dextrose (D-glucose) is indispensable for advanced studies of glucose metabolism and tumor immunometabolism, providing high solubility, purity, and workflow flexibility. This guide demystifies experimental setup, protocol optimization, and troubleshooting for researchers leveraging D-glucose in complex cellular models, translating cutting-edge findings into actionable lab strategies.

• Phytol (SKU C5616): Reliable RXR and GABA Modulation in Assa

  2026-05-14

  This article provides an evidence-driven, scenario-based guide for leveraging Phytol (SKU C5616) to overcome common challenges in cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed literature and APExBIO’s validated product specifications, it details how Phytol delivers reproducibility and workflow confidence for biomedical researchers.

• BKT140 (BL-8040) CXCR4 Antagonist: Applied Oncology Workflow

  2026-05-13

  BKT140 (BL-8040, TF 14016) empowers oncology researchers with precision CXCR4 inhibition, validated for workflows in tumor microenvironment studies and stem cell mobilization. This guide delivers actionable protocol enhancements, troubleshooting strategies, and insights from the latest theranostic research.

• Biomimetic α-Cyperone Nanoparticles Mitigate Ovarian Inflamm

  2026-05-13

  This study introduces a dual-targeted, biomimetic nanoparticle system for α-cyperone delivery to granulosa cells, effectively reducing LPS-induced inflammation through Nrf2/HO-1 pathway activation and ROS suppression. The findings highlight a promising nanotechnological approach for addressing diminished ovarian reserve and related inflammatory damage.

• Copper-Catalyzed Radical Cyclization for Thioazafluoranthene

  2026-05-12

  This study introduces a copper-catalyzed tandem radical cyclization enabling efficient synthesis of sulfur/nitrogen-doped fluoranthenes with notable fluorescence. The work expands polycyclic aromatic chemistry and provides a new route to biologically and optoelectronically relevant scaffolds.

• Identification and Characterization of a Novel Ziprasidone I

  2026-05-12

  This study reports the detection, isolation, and structural elucidation of a previously unreported impurity—methylene ziprasidone dimer (MZD)—in ziprasidone hydrochloride manufacturing batches. The findings enhance understanding of impurity profiles in atypical antipsychotic research and highlight the importance of advanced analytical methods for pharmaceutical quality control.

• Optimizing mRNA Delivery with EZ Cap EGFP mRNA 5-moUTP

  2026-05-11

  EZ Cap™ EGFP mRNA (5-moUTP) streamlines immune-silent, robust protein expression for gene regulation and in vivo imaging studies. Its Cap 1 structure and 5-methoxyuridine modifications enable consistent, high-efficiency delivery—outperforming traditional mRNA reporter tools in stability and translational output.

• Toremifene Review: Two Decades of Endocrine Therapy in Breas

  2026-05-11

  This review analyzes 20 years of clinical data on toremifene, a selective estrogen receptor modulator (SERM), highlighting its efficacy and safety in the treatment of estrogen receptor-positive breast cancer. The findings support individualized therapeutic strategies, emphasizing biomarker-driven approaches and the importance of understanding pharmacokinetics in endocrine therapy.

• SB 431542 in Immune-Trophoblast Research: Beyond Standard AL

  2026-05-10

  Explore how SB 431542, a potent ALK5 inhibitor, revolutionizes immunological studies of human extravillous trophoblasts. This article uniquely connects TGF-β signaling inhibition with advanced maternal-fetal interface research, providing deeper insights and optimized protocols.

• ER Stress via GRP78/ATF6/CHOP Pathway Impairs Intestinal Ste

  2026-05-09

  This study demonstrates that endoplasmic reticulum (ER) stress, induced by tunicamycin, activates the GRP78/ATF6/CHOP signaling axis in mouse intestines, resulting in reduced intestinal stem cell numbers and impaired differentiation. These findings clarify the molecular consequences of ER stress on gut homeostasis and suggest mechanistic intersections with established cell cycle arrest agents.

• Lyotropic Assembly of Coil-Bottlebrush Diblocks in Ionic Liq

  2026-05-09

  This study investigates how coil-bottlebrush diblock copolymers self-assemble into nanostructured network morphologies within alkylimidazolium-based ionic liquids. The findings reveal that lyotropic phase behavior is surprisingly insensitive to variations in ionic liquid structure, offering new insights for designing advanced nanomaterials with tunable properties.

• miR-196a Drives Esophageal Adenocarcinoma via MYC/TERT/NFκB

  2026-05-08

  This study identifies microRNA-196a (miR-196a) as a direct promoter of esophageal adenocarcinoma (EAC) aggressiveness via the MYC/TERT/NFκB signaling axis. The work provides mechanistic evidence that miR-196a orchestrates epithelial–mesenchymal transition and tumor progression, underscoring c-Myc as a key vulnerability for targeted intervention.

• Phytol: Advancing RXR Activation and GABAergic Modulation in

  2026-05-07

  Explore the multifaceted roles of Phytol in retinoid X receptor signaling and GABAergic transmission modulation. This article provides a uniquely in-depth analysis of Phytol’s mechanisms, assay considerations, and translational opportunities for laboratory innovation.

• WNT5a/GSK3/β-catenin Axis Regulates FAP Adipogenesis in Musc

  2026-05-07

  This study uncovers how the WNT5a/GSK3/β-catenin pathway governs adipogenic differentiation of skeletal muscle fibro/adipogenic progenitors (FAPs). Through multi-modal analysis, the authors demonstrate that modulating this axis can constrain fatty degeneration in muscle, offering novel targets for myopathy research.

• Nilotinib (AMN-107): Beyond Kinase Inhibition in Cancer Immu

  2026-05-06

  Explore how Nilotinib (AMN-107) from APExBIO not only targets BCR-ABL in chronic myeloid leukemia research, but also reprograms tumor immunogenicity. This article unveils new mechanisms and practical protocols for leveraging Nilotinib in next-generation cancer models.

449 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page